TheranosticTrials.org

Clinical Trial · NCT07914764

68Ga-labeled Cholecystokinin Receptor (CCK2R) Targeted Molecular Probes in Early Tumor Diagnosis

Overview

Evaluate the safety of the novel radioactive nuclide-labeled cholecystokinin receptor (CCK2R) targeted molecular probe, 68Ga-YQ-CC05, in clinical application, and verify its effectiveness in tumor diagnosis.

Sponsor

Nanjing First Hospital, Nanjing Medical University

Contacts

Feng Wang (CONTACT)

fengwangcn@hotmail.com

+8602552271491

ClinicalTrials.gov

NCT07914764

Drug / Compound

YQ-CC05

Isotope(s):
Target(s):
  • CCK2R
Ligand Class: Peptides

Eligibility

Inclusion

  • Tumor patients who can obtain the final pathological results.
  • Other imaging examination methods (CT, MRI, etc.) reveal tumor occupying lesions;
  • Kidney: GFR \> 50 ml/min, ERPF \> 280 ml/min, platelet count (PLT) \> 75,000/μL, white blood cell (WBC) \> 3,000/μL, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than 3 times the normal value.

Exclusion

  • Individuals with a history of allergy to similar drugs (drugs with similar chemical or biological components to CCK2R), allergic constitution, or current allergic diseases;
  • Having severe acute concomitant diseases or severe treatment-resistant mental disorders;
  • Other uncontrollable clinical issues (such as HIV, hepatitis C virus infection, active hepatitis B, or other severe chronic infections, as well as severe mental, neurological, cardiovascular, respiratory, and other systemic diseases);
  • Tumor burden greater than 50%, or significant spinal cord compression;
  • Obvious abnormalities in liver and kidney function, with GFR less than 50 ml/min;
  • Pregnant and lactating women (where pregnancy is defined as a positive urine pregnancy test result);
  • Those who are currently participating in other clinical drug studies, or have previously participated in any clinical drug studies (excluding vitamins and minerals);
  • Patients who are physically unfit for radiological examinations;
  • Other situations where the researcher deems it inappropriate for the participant to participate in the trial.
  • Expected survival duration less than half a year; chemotherapy within 6 months;
  • Red blood cells (RBC) count less than 4×10\^12, white blood cells (WBC) count less than 3×10\^9, hemoglobin level less than 110g/L, and platelet count (PLT) less than 75,000×10\^9;